Thus, these observations: (1) identify Cdk6 as an early molecular marker of colitis-associated progression, both in preclinical models and in humans with UC; and (2) confirm the clinical relevance of the AOM/DSS model of colitis-associated carcinogenesis. This evidence concerns the gene CDK6 and colitis.